ESC 365 - Doctor Ewelina Kulikowski

Speaker illustration

Doctor Ewelina Kulikowski

Calgary (Canada)

Member of:

Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial

Event: ESC Congress 2024

Topic: Fibrosis

Session: Epigenetic targets in cardiovascular disease

Apabetalone, a BET inhibitor, attenuates inflammation induced by viral RNA mimetic and reduces SARS-CoV-2 spike protein binding regardless of variants

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Pericardial disease, myocardial disease, COVID-19

Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

Event: ESC Congress 2019

Topic: Inflammation and Immunity

Session: Coronary artery disease inflammation

Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta

Event: ESC Congress 2018

Topic: Genetics, Epigenetics, ncRNA

Session: Late Breaking Basic and Translational Science - Vascular Biology

Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment

Event: ESC Congress 2017

Topic: CAD and comorbidities

Session: CAD and comorbidities

Modulation of the complement cascade in cardiovascular disease patients by a bromodomain and extraterminal (BET) protein inhibitor

Event: ESC Congress 2016

Topic: Inflammation and microcirculation

Session: Inflammation and immunity

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources